Abstract
Mutations in the TSC1 or TSC2 genes cause tuberous sclerosis, a benign tumour syndrome in humans1,2. Tsc2 possesses a domain that shares homology with the GTPase-activating protein (GAP) domain of Rap1-GAP2, suggesting that a GTPase might be the physiological target of Tsc2. Here we show that the small GTPase Rheb (Ras homologue enriched in brain) is a direct target of Tsc2 GAP activity both in vivo and in vitro. Point mutations in the GAP domain of Tsc2 disrupted its ability to regulate Rheb without affecting the ability of Tsc2 to form a complex with Tsc1. Our studies identify Rheb as a molecular target of the TSC tumour suppressors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
van Slegtenhorst, M. et al. Science 277, 805–808 (1997).
The European Chromosome 16 Tuberous Sclerosis Consortium. Cell 75, 1305–1315 (1993).
Gao, X. & Pan, D. Genes Dev. 15, 1383–1392 (2001).
Potter, C.J., Huang, H. & Xu, T. Cell 105, 357–368 (2001).
Tapon, N., Ito, N., Dickson, B.J., Treisman, J.E. & Hariharan, I.K. Cell 105, 345–355 (2001).
Gao, X. et al. Nature Cell Biol. 4, 699–704 (2002).
Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K.L. Nature Cell Biol. 4, 648–657 (2002).
Radimerski, T., Montagne, J., Hemmings-Mieszczak, M. & Thomas, G. Genes Dev. 16, 2627–2632 (2002).
Tee, A.R. et al. Proc. Natl Acad. Sci. USA 99, 13571–13576 (2002).
Maheshwar, M.M. et al. Hum. Mol. Genet. 6, 1991–1996 (1997).
Saucedo, L.J. et al. Nature Cell Biol. 5, 566–571 (2003).
Stocker H. et al. Nature Cell Biol. 5, 559–565 (2003).
Xiao, G.-H., Shoarinejad, F., Jin, F., Golemis, E.A. & Yeung, R.S. J. Biol. Chem. 272, 6097–6100 (1997).
Wienecke, R., Konig, A. & DeClue, J.E. J. Biol. Chem. 270, 16409–16414 (1995).
Yamagata, K. et al. J. Biol. Chem. 269, 16333–16339 (1994).
Im, E. et al. Oncogene 21, 6356–6365 (2002).
Langille, S.E. et al. J. Biol. Chem. 274, 27099–27104 (1999).
Matsumoto, S., Bandyopadhyay, A., Kwiatkowski, D.J., Maitra, U. & Matsumoto, T. Genetics 161, 1053–1063 (2002).
Brinkmann, T. et al. J. Biol. Chem. 277, 12525–12531 (2002).
Garrett, M.D., Self, A.J., van Oers, C. & Hall, A. J. Biol. Chem. 264, 10–13 (1989).
Acknowledgements
We would like to thank E. Chen and K. Wharton for critical reading of the manuscript, G. Tall for advice on in vitro GAP assays and M. White for the GST–DRas1 construct. D.J.P. is Virginia Murchison Linthicum Endowed Scholar in Medical Science. This work was supported by grants from the National Institutes of Health (GM20590 to L.J.S.; GM51186 to B.A.E. and GM62323 to D.J.P.), American Heart Association (0130222N to D.J.P.) and the American Cancer Society (RSG0303601DDC to D.J.P.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Zhang, Y., Gao, X., Saucedo, L. et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5, 578–581 (2003). https://doi.org/10.1038/ncb999
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncb999
This article is cited by
-
mTORC1 in energy expenditure: consequences for obesity
Nature Reviews Endocrinology (2024)
-
Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis
Arthritis Research & Therapy (2023)
-
Perfect match: mTOR inhibitors and tuberous sclerosis complex
Orphanet Journal of Rare Diseases (2022)
-
Renal phenotypes correlate with genotypes in unrelated individuals with tuberous sclerosis complex in China
Orphanet Journal of Rare Diseases (2022)
-
GOLPH3 protein controls organ growth by interacting with TOR signaling proteins in Drosophila
Cell Death & Disease (2022)